Does the media favor ORKA or VIR?

In the previous week, Oruka Therapeutics had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 6 mentions for Oruka Therapeutics and 2 mentions for Vir Biotechnology. Oruka Therapeutics' average media sentiment score of 0.41 beat Vir Biotechnology's score of 0.10 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DNTH or VIR?

In the previous week, Dianthus Therapeutics had 12 more articles in the media than Vir Biotechnology. MarketBeat recorded 14 mentions for Dianthus Therapeutics and 2 mentions for Vir Biotechnology. Dianthus Therapeutics' average media sentiment score of 1.01 beat Vir Biotechnology's score of 0.10 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VIR or LGND?

In the previous week, Ligand Pharmaceuticals had 2 more articles in the media than Vir Biotechnology. MarketBeat recorded 4 mentions for Ligand Pharmaceuticals and 2 mentions for Vir Biotechnology. Ligand Pharmaceuticals' average media sentiment score of 0.40 beat Vir Biotechnology's score of 0.10 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ligand Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VIR or TVTX?

In the previous week, Travere Therapeutics had 9 more articles in the media than Vir Biotechnology. MarketBeat recorded 11 mentions for Travere Therapeutics and 2 mentions for Vir Biotechnology. Travere Therapeutics' average media sentiment score of 1.18 beat Vir Biotechnology's score of 0.10 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vir Biotechnology (VIR) Competitors

$9.78 +0.57 (+6.19%)

As of 08/21/2026 04:00 PM Eastern

Compare

VIR vs. ORKA, DNTH, KNSA, LGND, and TVTX

Should you buy Vir Biotechnology stock or one of its competitors? Vir Biotechnology's main competitors and comparable companies include Oruka Therapeutics (ORKA), Dianthus Therapeutics (DNTH), Kiniksa Pharmaceuticals International (KNSA), Ligand Pharmaceuticals (LGND), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vir Biotechnology compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oruka Therapeutics currently has a consensus target price of $134.30, indicating a potential upside of 24.40%. Vir Biotechnology has a consensus target price of $20.63, indicating a potential upside of 110.89%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

Oruka Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Vir Biotechnology	$68.56M	24.14	-$437.99M	-$1.86	N/A

In the previous week, Oruka Therapeutics had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 6 mentions for Oruka Therapeutics and 2 mentions for Vir Biotechnology. Oruka Therapeutics' average media sentiment score of 0.41 beat Vir Biotechnology's score of 0.10 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oruka Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Oruka Therapeutics' return on equity of -21.65% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

Summary

Oruka Therapeutics and Vir Biotechnology tied by winning 8 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Dianthus Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,977.37	-$162.34M	-$4.15	N/A
Vir Biotechnology	$68.56M	24.14	-$437.99M	-$1.86	N/A

Dianthus Therapeutics currently has a consensus price target of $124.27, indicating a potential upside of 11.86%. Vir Biotechnology has a consensus price target of $20.63, indicating a potential upside of 110.89%. Given Vir Biotechnology's higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Dianthus Therapeutics had 12 more articles in the media than Vir Biotechnology. MarketBeat recorded 14 mentions for Dianthus Therapeutics and 2 mentions for Vir Biotechnology. Dianthus Therapeutics' average media sentiment score of 1.01 beat Vir Biotechnology's score of 0.10 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dianthus Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

Vir Biotechnology has a net margin of -638.88% compared to Dianthus Therapeutics' net margin of -10,096.95%. Dianthus Therapeutics' return on equity of -22.53% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Dianthus Therapeutics beats Vir Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	9.10	$59.01M	$0.97	81.47
Vir Biotechnology	$68.56M	24.14	-$437.99M	-$1.86	N/A

Kiniksa Pharmaceuticals International presently has a consensus target price of $87.38, indicating a potential upside of 10.56%. Vir Biotechnology has a consensus target price of $20.63, indicating a potential upside of 110.89%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Vir Biotechnology's net margin of -638.88%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

Kiniksa Pharmaceuticals International has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Vir Biotechnology had 1 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 2 mentions for Vir Biotechnology and 1 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.63 beat Vir Biotechnology's score of 0.10 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vir Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kiniksa Pharmaceuticals International beats Vir Biotechnology on 10 of the 17 factors compared between the two stocks.

How does Vir Biotechnology compare to Ligand Pharmaceuticals?

Vir Biotechnology (NASDAQ:VIR) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Vir Biotechnology's net margin of -638.88%. Ligand Pharmaceuticals' return on equity of 20.06% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ligand Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	24.14	-$437.99M	-$1.86	N/A
Ligand Pharmaceuticals	$268.09M	21.29	$124.45M	$9.35	30.62

In the previous week, Ligand Pharmaceuticals had 2 more articles in the media than Vir Biotechnology. MarketBeat recorded 4 mentions for Ligand Pharmaceuticals and 2 mentions for Vir Biotechnology. Ligand Pharmaceuticals' average media sentiment score of 0.40 beat Vir Biotechnology's score of 0.10 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vir Biotechnology currently has a consensus target price of $20.63, suggesting a potential upside of 110.89%. Ligand Pharmaceuticals has a consensus target price of $335.75, suggesting a potential upside of 17.28%. Given Vir Biotechnology's higher probable upside, equities research analysts clearly believe Vir Biotechnology is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Vir Biotechnology has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Summary

Ligand Pharmaceuticals beats Vir Biotechnology on 13 of the 17 factors compared between the two stocks.

How does Vir Biotechnology compare to Travere Therapeutics?

Vir Biotechnology (NASDAQ:VIR) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Vir Biotechnology presently has a consensus price target of $20.63, indicating a potential upside of 110.89%. Travere Therapeutics has a consensus price target of $61.67, indicating a potential downside of 6.15%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, research analysts clearly believe Vir Biotechnology is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Travere Therapeutics has higher revenue and earnings than Vir Biotechnology. Travere Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	24.14	-$437.99M	-$1.86	N/A
Travere Therapeutics	$490.73M	12.62	-$25.55M	-$0.46	N/A

In the previous week, Travere Therapeutics had 9 more articles in the media than Vir Biotechnology. MarketBeat recorded 11 mentions for Travere Therapeutics and 2 mentions for Vir Biotechnology. Travere Therapeutics' average media sentiment score of 1.18 beat Vir Biotechnology's score of 0.10 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

65.3% of Vir Biotechnology shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Travere Therapeutics has a net margin of -7.35% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Vir Biotechnology has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Summary

Travere Therapeutics beats Vir Biotechnology on 9 of the 17 factors compared between the two stocks.

Get Vir Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIR vs. The Competition

Export

Metric	Vir Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.65B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-5.26	11.62	272.60	24.24
Price / Sales	24.14	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	1.68	16.80	13.05	6.20
Net Income	-$437.99M	-$12.50M	$3.47B	$348.59M
7 Day Performance	5.84%	3.29%	2.09%	0.08%
1 Month Performance	4.71%	8.23%	6.64%	3.88%
1 Year Performance	113.54%	55.05%	25.02%	16.98%

Vir Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIR Vir Biotechnology	2.0514 of 5 stars	$9.78 +6.2%	$20.63 +110.9%	+113.5%	$1.65B	$68.56M	N/A	580
ORKA Oruka Therapeutics	3.454 of 5 stars	$105.14 +6.4%	$134.30 +27.7%	+599.2%	$5.96B	N/A	N/A	N/A
DNTH Dianthus Therapeutics	2.877 of 5 stars	$111.80 +2.6%	$124.27 +11.2%	+357.2%	$5.95B	$2.04M	N/A	80	News Coverage Positive News Insider Trade
KNSA Kiniksa Pharmaceuticals International	3.9637 of 5 stars	$76.53 +0.6%	$87.38 +14.2%	+134.2%	$5.93B	$677.56M	78.90	220	Positive News
LGND Ligand Pharmaceuticals	3.7464 of 5 stars	$295.70 +0.9%	$336.57 +13.8%	+80.0%	$5.88B	$268.09M	31.63	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIR) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vir Biotechnology (VIR) Competitors

VIR vs. ORKA, DNTH, KNSA, LGND, and TVTX

How does Vir Biotechnology compare to Oruka Therapeutics?

Summary

How does Vir Biotechnology compare to Dianthus Therapeutics?

Summary

How does Vir Biotechnology compare to Kiniksa Pharmaceuticals International?

Summary

How does Vir Biotechnology compare to Ligand Pharmaceuticals?

Summary

How does Vir Biotechnology compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vir Biotechnology (VIR) Competitors

VIR vs. ORKA, DNTH, KNSA, LGND, and TVTX

How does Vir Biotechnology compare to Oruka Therapeutics?

Do insiders and institutionals believe in ORKA or VIR?

Do analysts rate ORKA or VIR?

Which has more volatility and risk, ORKA or VIR?

Which has higher valuation and earnings, ORKA or VIR?

Does the media favor ORKA or VIR?

Is ORKA or VIR more profitable?

Summary

How does Vir Biotechnology compare to Dianthus Therapeutics?

Which has higher earnings and valuation, DNTH or VIR?

Do analysts prefer DNTH or VIR?

Does the media prefer DNTH or VIR?

Which has more volatility and risk, DNTH or VIR?

Is DNTH or VIR more profitable?

Do insiders & institutionals believe in DNTH or VIR?

Summary

How does Vir Biotechnology compare to Kiniksa Pharmaceuticals International?

Which has preferable valuation and earnings, KNSA or VIR?

Do analysts prefer KNSA or VIR?

Is KNSA or VIR more profitable?

Which has more risk & volatility, KNSA or VIR?

Do insiders and institutionals believe in KNSA or VIR?

Does the media prefer KNSA or VIR?

Summary

How does Vir Biotechnology compare to Ligand Pharmaceuticals?

Is VIR or LGND more profitable?

Do institutionals and insiders hold more shares of VIR or LGND?

Which has preferable valuation and earnings, VIR or LGND?

Does the media refer more to VIR or LGND?

Do analysts recommend VIR or LGND?

Which has more volatility & risk, VIR or LGND?

Summary

How does Vir Biotechnology compare to Travere Therapeutics?

Do analysts recommend VIR or TVTX?

Which has stronger earnings & valuation, VIR or TVTX?

Does the media refer more to VIR or TVTX?

Do institutionals & insiders hold more shares of VIR or TVTX?

Is VIR or TVTX more profitable?

Which has more volatility and risk, VIR or TVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools